Interaction of Osteopontin with IL-18 in Obese Individuals: Implications for Insulin Resistance

Rasheed Ahmad1*, Anfal Al-Mass1, Dalal Al-Ghawas1, Nada Shareif1, Nadia Zghoul1, Motasem Melhem2, Amal Hasan1, Fahad Al-Ghimlas3, Said Dermime1, Kazem Behbehani4

1 Immunology and Innovative Cell Therapy Unit, Dasman Diabetes Institute, Kuwait City, Kuwait, 2 Genetics and Genomics Unit, Dasman Diabetes Institute, Kuwait City, Kuwait, 3 Fitness and Rehabilitation Center, Dasman Diabetes Institute, Kuwait City, Kuwait, 4 Senior Management, Dasman Diabetes Institute, Kuwait City, Kuwait

Abstract

**Background/Objective:** Osteopontin (OPN) and IL-18 are known inflammatory mediators and both participate in a wide range of biological processes linked to immunological disorders. Since an interaction between OPN and IL-18 has not been studied in obesity, we investigated whether: (i) their levels were simultaneously elevated in obese individuals; (ii) OPN was associated with IL-18 in obese individuals and (iii) their levels associated with fasting blood glucose (FBG) and BMI.

**Subjects and Methods:** PBMCs and plasma samples were isolated from 60 individuals including lean as well as overweight and obese individuals. Subcutaneous adipose tissue samples were obtained. OPN and IL-18 were measured by ELISA. OPN and IL-18 mRNA expression was quantified by real time quantitative RT-PCR.

**Results:** Obese individuals exhibited significantly increased circulating OPN levels as compared with lean individuals (obese 2865±101; lean 1681±116 pg/ml; P<0.0001). IL-18 levels were also high in obese individuals (obese 491±39, lean 301±26 pg/ml, P<0.0009). OPN and IL-18 expression were simultaneously up-regulated (OPN: 5.4-Fold; IL-18: 8.9-Fold; P<0.05) in PBMCs from obese individuals compared to lean group. Adipose tissue from obese individuals had high expression of OPN (7.3-Fold) and IL-18 (9.6-Fold). Plasma OPN levels correlated positively with FBG levels (r = 0.32, P = 0.02). Similarly, IL-18 correlated positively with FBG levels (r = 0.406, P = 0.0042). Stepwise multiple regression analysis showed an independent association of BMI with OPN and IL-18. Interestingly, OPN levels increased progressively with an increase in IL-18 levels (r = 0.52, P = 0.0004). We also examined the regulatory role of IL-18 in OPN secretion from PBMCs. Neutralizing anti-IL-18R mAb reduced OPN secretion.

**Conclusion:** These findings represent the first observation that plasma, PBMC and adipose tissue OPN and IL-18 are simultaneously increased and correlate with each other in overweight/obese individuals which may trigger the development of obesity-associated insulin resistance. Moreover, these results provide the direct evidence that IL-18 regulates OPN production in PBMCs.

Introduction

Obesity induces chronic, low-grade tissue inflammation which is important in the development of obesity-related pathologies, such as insulin resistance and type 2 diabetes, and cardiovascular disease [1,2,3]. The cause and stimulus of persistent inflammatory activation in obesity remain largely unknown. Levels of circulating inflammatory biomarkers such as high-sensitivity C-reactive protein hsCRP, tumor necrosis factor receptor (TNF-αR), Interlukin-6 (IL-6), soluble tumor necrosis factor receptor 2 (sTNFR2), and cellular adhesion molecules are consistently elevated in the obese patients and normally correlate with parameters of adiposity, risk factors of cardiovascular diseases, insulin resistance, and type 2 diabetes risks [4,5,6,7]. Adipocytes, monocytes, and macrophages are actively involved in the secretion of proinflammatory cytokines [8] 2010. In case of obesity, the levels of activated monocytes and macrophages are elevated. A positive correlation was found between body mass index (BMI) and percentage of macrophages, suggesting that fat tissue growth was associated with recruitment of blood monocytes. Activated monocytes infiltrate the adipose tissues and contribute significantly to sustain chronic inflammation through synthesis and increase of cytokines that may be etiologically intertwined with the mechanisms of obesity-induced insulin resistance [9,10].

OPN is a multifunctional proinflammatory cytokine, a glycoprotein that is secreted by activated T cells, NK cells, dendritic cells and monocytes/macrophages and plays a major role in cell-mediated immunity [11,12,13]. OPN is one of the key factors which are actively involved in macrophage recruitment during inflammatory processes. It interacts with the integrin surface receptors through an Arg-Gly-Asp (RGD) sequence and with the
CD44 receptor to induce signaling [14]. Macrophages at sites of inflammation are prolific producers of this cytokine which mediates monocyte adhesion, migration, differentiation, and phagocytosis [13,16,17,18]. In adipose tissue, OPN induces infiltration and activation of macrophages and these infiltrated macrophages produce proinflammatory cytokines which contribute to adipose tissue insulin resistance [19].

IL-18 is a potent proinflammatory cytokine that belongs to the IL-1 superfamily and is produced by monocytes/macrophages and other cells [20]. In addition to monocyte/macrophages, IL-18 is also produced by adipose tissue [21] and higher circulating levels are found in obese than lean individuals. Both OPN and IL-18 participate in a wide range of potent inflammatory processes that are linked to immunological disorders. Mechanistically, IL-18 activates the transcriptional factors AP-1 and NF-κB in T lymphocytes and these factors are also involved in the transcriptional upregulation of OPN gene [22,23,24,25]. Increasing evidence shows that circulatory levels of both inflammatory mediators are elevated in obese individuals [26,27,28,29]. However, it is unclear whether both inflammatory mediators (cytokines) are simultaneously increased in obesity and also the interaction between two inflammatory mediators is so far not known. The data presented herein clarify the regulatory role of IL-18 regarding OPN expression in plasma, PBMC and adipose tissue, and also show their correlation with BMI and fasting blood glucose levels.

Methods

Participants and Clinical Parameters

Our department (Biomedical research) carried out a study with the collaboration of Fitness and Rehabilitation Center. Subjects were recruited by different advertisements. Participants were offered a cost free 6 month’s exercise program at Fitness and Rehabilitation Center. Before joining the program, subjects were examined at local clinic by medical physician. Subjects of both male and female were included if they (1) are older than 18 years with BMI less than 40 Kg/m², (2) no previous exercise program at least one year prior to the study. Subjects were excluded if they (1) were morbid obese, (2) were unable to do exercise and (3) had major illness. Subjects who are diabetic were on antidibetic drugs (metformin, sulfourea, glitazone and exenatid. 60 adult individuals treated with rhIL-18 (20 ng/ml) for 16 hours. PBMCs and culture supernatant and cells were collected for analysis of OPN expression.

Subcutaneous Adipose Tissue Biopsy

Human adipose tissue was collected via abdominal subcutaneous fat pad biopsy lateral to the umbilicus using standard sterile technique. Adipose tissue samples were obtained from 9 individuals with different BMI. Tissue samples were stored in RNA-later RNA stabilization reagent (Qiagen) and stored at −80°C until use.

Neutralization of IL-18 Receptor with Antibody

PBMCs were incubated with IL-18Ra monoclonal antibody and isotype-matched control antibody (mouse IgG1; R&D Systems) at a concentration of 0.1 ug/ml for 30 minutes and then treated with rhIL-18 (20 ng/ml) for 16 hours. PBMCs and culture supernatant and cells were collected for analysis of OPN expression.

Table 1. Characteristics of the study participants.

| Characteristic | Lean (BMI<25) | Overweight (25<BM<30) | Obese (30<BM<40) |
|----------------|-------------|----------------------|------------------|
| Age range (Years) | 26–46 | 28–43 | 28–46 |
| BMI | 22.71±0.33 | 27.77±0.33 | 34.00±0.55 |
| Glu (mmol/l) | 4.91±0.17 | 6.12±0.47 | 5.84±0.36 |
| HbA1C (%) | 5.46±0.08 | 6.34±0.44 | 6.05±0.2 |
| Chol (mmol/l) | 4.89±0.20 | 5.06±0.21 | 5.54±0.19 |
| HDL (mmol/l) | 1.24±0.08 | 1.2±0.07 | 1.14±0.06 |
| LDL (mmol/l) | 3.24±0.18 | 3.10±0.16 | 3.58±0.19 |
| TGL (mmol/l) | 0.82±0.13 | 0.80±0.17 | 1.79±0.20 |

doi:10.1371/journal.pone.0063944.t001
supernatant were analyzed for OPN mRNA and protein, respectively.

**Enzyme-linked Immunosorbent Assay**

Concentrations of OPN and IL-18 in plasma and culture supernatants were determined using commercial enzyme-linked immunosorbent assay kits (R & D Systems) according to the manufacturer’s recommendation.

**Real Time Quantitative RT-PCR**

Total RNA was extracted using RNeasy Mini Kit (Qiagen). The cDNA was synthesized using 1 ug of total RNA using high capacity cDNA reverse transcription kit (Invitrogen). 50 ng cDNA and 3 pmol of both forward and reverse primers were used in each real time PCR reaction. Real time PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems) on 7500 real time PCR System (Applied Biosystems). All PCR reactions were performed in duplicate. The primers are used as follows: OPN Fwd (5'-AGGAGGACGCCCCAGCCAGCA-3') and OPN Rev (5'-CTGGTATGGCATCACCCAGTGG-3'); IL-18 Fwd (5'-GAAAAATTTCACTCTCTCTGTCG-3') and IL-18 Rev (5'-CTTCGTATGATGAGATGACG-3'); GAPDH Fwd (5'-ATGGGGGAAGGTGAAGGTC-3') and GAPDH Rev (5'-GAGGTCAATGGAAGGGGTGAC-3'). The mRNA levels were normalized against GAPDH mRNA and the amounts of OPN or IL-18 -mRNA relative to control were calculated with ΔCt method [31]. Relative mRNA expression was expressed as fold expression over average of gene expression of lean group. The expression level in lean group was assumed to be 1. Values are presented as mean ± SEM.

**Statistical Analysis**

Statistical analysis was performed using GraphPad Prism software (La Jolla, CA, USA) and SPSS for Windows version 19.01 (IBM SPSS Inc., USA). Data are shown as mean ± standard deviation values, unless otherwise indicated. Unpaired Student t-test and Wilcoxon signed-rank test were used to compare means between groups. Correlation, linear regression and stepwise multiple regression analysis were performed to determine association between different variables. For all analyses, P value <0.05 was considered significant.

**Results**

**Elevated Levels of Plasma IL-18 and OPN in Obese Individuals**

IL-18 and OPN are considered important mediators of both immunological and pathological disorders. The levels of both mediators have been studied separately in obese individuals and have been found at high levels. Since no study has been done related to the measurement of these mediators in the same individuals, we conducted a cross-sectional study and measured simultaneously plasma levels of IL-18 and OPN from lean (n: 16), overweight (n: 20) and obese (n: 24) individuals. As shown in Fig. 1A and B, increased concentrations of OPN and IL-18 were found in obese as compared with lean individuals. Plasma from obese individuals showed significantly increased levels of OPN compared to lean individuals (obese 2865 ± 101, overweight 2196 ± 148, lean 1681 ± 116 pg/ml; P < 0.01). In parallel, plasma IL-18 levels were also increased (P = 0.0009) in obese individuals as compared with those of lean individuals. Plasma from obese individuals showed significantly increased levels of OPN compared to lean individuals (obese 2865 ± 101, overweight 2196 ± 148, lean 1681 ± 116 pg/ml; P < 0.01). In parallel, plasma IL-18 levels were also increased (P = 0.0009) in obese individuals as compared with those of lean individuals.

**Increased Expression of OPN and IL-18 in PBMCs of Obese Individuals**

As PBMCs are the main source for the production of both IL-18 and OPN, we next determined mRNA expression of OPN and IL-18 in PBMCs from lean (n: 16), overweight (n: 20) and obese (n: 24) individuals. mRNA expression of OPN and IL-18 was analyzed by quantitative real time RT-PCR. The level of OPN expression in the PBMCs from overweight and obese individuals was significantly higher (Obese: 5.4 Fold; Overweight: 3.9-Fold higher; P < 0.05) than that in the control group. IL-18 expression in PBMCs from overweight and obese individuals was significantly higher (Obese: 5.4 Fold; Overweight: 3.9-Fold higher; P < 0.05) than that in the control group.
lean individuals (obese 73.96 ± 6.78, lean 45.73 ± 5.03 pg/ml; P = 0.028).

Elevated Expression of OPN and IL-18 in Adipose Tissue

Several studies suggest that adipose tissue is considered as an endocrine organ that produces and secretes a variety of cytokines, hormones and other metabolic players involved in the pathogenesis of obesity. Among this versatile group of mediators and effectors of inflammation, we have studied the expression of OPN and IL-18. All these markers, in their circulatory form, have been found. However, there is no much data available on their simultaneous expression in adipose tissue in human subjects. We isolated total RNA from subcutaneous fat biopsies from 9 individuals with different BMI values. We then measured RNA expression of OPN and IL-18 using quantitative real time RT-PCR. OPN and IL-18 were highly expressed in obese individuals (OPN: 7.3 Fold; IL-18: 9.6 Fold; P < 0.05) as compared with those with normal BMI (Fig. 3A and B). Overall inflammatory activity, in addition to adipose tissue mass, provided information on a pathogenetic link between obesity and OPN and IL-18.

Figure 2. Expression of OPN and IL-18 by PBMCs. Total RNA was extracted from PBMCs of 60 individuals with different BMI (lean: 16; overweight: 20; obese 24). OPN and IL-18 mRNA were measured by real time quantitative PCR. Relative mRNA expression was expressed as fold expression over average of gene expression of lean group. The expression level in lean group was assumed to be 1. Values are presented as mean ± SE (A and B). PBMCs from three donors of each group were cultured in RPMI supplemented with 2% FBS for 16 hours and then culture supernatants were collected. Secreted OPN protein was determined in the culture supernatants by ELISA (C). Data presented were the means of three independent experiments performed with PBMCs of three donors of each group with ± SE. doi:10.1371/journal.pone.0063944.g002

Association between OPN and IL-18 in Obese Individuals

As our data show that OPN and IL-18 mRNA and protein levels were elevated in obese individuals, therefore, we investigated whether OPN had a relationship with IL-18 in obese individuals. To this end, we determined correlation between plasma OPN and IL-18 levels. As shown in Fig. 4A, we found a linear regression (r = 0.52, P = 0.0004) between IL-18 and OPN in obese individuals and overweight population. In addition, we observed a highly significant association (r = 0.91, P = 0.01) between OPN and IL-18 mRNA expression (Fold changes) in subcutaneous adipose tissue. (Fig. 4B). IL-18 gene expression (Fold changes) was significantly associated with OPN gene expression (Fold changes) in PBMCs from overweight and obese individuals (Fig. 4C; r = 0.45, P = 0.002). These results suggest that up-regulated IL-18 expression may contribute to increased OPN expression in obese individuals.

OPN Expression was Induced in PBMCs by rhIL-18

Since both OPN and IL-18 were found elevated in obese individuals, IL-18 could activate OPN expression in the PBMCs.
Figure 3. Expression of OPN and IL-18 mRNA in adipose tissue. Adipose tissue samples from 9 (lean: 3, overweight: 3 and obese: 3) individuals with different BMI were subjected to total RNA isolation. OPN and IL-18 mRNA expression was determined by real time quantitative RT-PCR. Relative mRNA expression was expressed as fold expression over average of gene expression of lean group. The expression level in lean group was assumed to be 1. Values are presented as mean ± SE (A and B).

doi:10.1371/journal.pone.0063944.g003

Figure 4. Linear regression between OPN and IL-18. Plasma OPN and IL-18 levels were determined by ELISA. There was a statistical significant linear regression between OPN and IL-18 ($r = 0.52$, $P = 0.0004$, $n = 44$) in obese and overweight individuals which were free from overweight/obesity induced major complications (A). A strong association of OPN mRNA (Fold change) with IL-18 mRNA was observed in adipose tissue ($r = 0.91$, $P = 0.01$) (B). Fold change expression of OPN and IL-18 mRNA in PBMCs of 44 overweight and obese individuals was correlated with each other ($r = 0.45$, $P = 0.0018$) (C).

doi:10.1371/journal.pone.0063944.g004
To check this, PBMCs were cultured in presence or absence of rhIL-18. An increased expression of OPN, both at mRNA (Fig. 5A) and protein levels (Fig. 5B), was observed in PBMCs stimulated with rhIL-18 (P = 0.003). On the other hand, neutralization of IL-18Rα with an anti-IL-18Rα mAb led to the inhibition of IL-18-induced OPN gene expression (P = 0.002). In this case, OPN gene expression levels were similar to those observed in untreated cells whereas there was no change in OPN expression in cells treated with isotype control antibody.

Association between Metabolic Parameters and OPN/IL-18

We further investigated whether the interaction between IL-18 and OPN had an effect on clinico-metabolic parameters. In this regard, serum levels of triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, lipoprotein, fasting blood glucose and HbA1C were also measured. FBG associated significantly with OPN (r = 0.32, P = 0.02) and IL-18 (r = 0.406, P = 0.0042) levels (Table 2). HDL, LDL, and cholesterol levels did not correlate with either IL-18 or OPN. However, BMI showed a strong correlation with IL-18 (r = 0.344, P = 0.016) and OPN (r = 0.499, P = 0.0002) levels. Moreover, FBG was significantly correlated with gene expression of OPN (r = 0.517, P < 0.0001) and IL-18 (r = 0.259, P = 0.045) in PBMCs. Similarly HbA1C was associated with gene expression of OPN (r = 0.404, P = 0.0014) and IL-18 (r = 0.267, P = 0.043). Stepwise multiple linear regression analysis was performed to identify clinical variables (metabolic parameters) associated with OPN or IL-18 as a dependent variable. This analysis revealed that plasma OPN and IL-18 are independently associated with BMI (P < 0.05) (Table 3). Similarly PBMC gene expression of OPN and IL-18 were also independently associated with BMI (P < 0.05). Moreover, circulating FBG was a predictor of IL-18 (P = 0.004) and circulating TGL is a predictor of OPN gene expression in PBMCs (P < 0.003) (Table 3).

**Discussion**

Obesity induces chronic, low-grade tissue inflammation which is responsible, at least in part, for the development of obesity-related pathologies such as insulin resistance and type 2 diabetes, as well as cardiovascular diseases [1,2,3]; however, the cause and stimulus of persistent inflammatory activation in obesity largely remains unknown. It is speculated that migration of the inflammatory monocytes to the adipose tissue can be a major factor involved in obesity-induced inflammation. Both OPN and IL-18 are known as key mediators involved in different immunological disorders. Previous studies have shown that these two inflammatory mediators are abnormally elevated in obese individuals [32,33,34]. It is noteworthy here that all the previous studies on OPN and IL-18 individually measured levels of these cytokines in different subject populations. To our knowledge, no study so far has shown that both inflammatory cytokines are simultaneously elevated in the same study population. Moreover, an interaction between OPN and IL-18 has not been elucidated. Here, our data show that plasma concentrations of OPN and IL-18 cytokines were simultaneously increased in obese individuals as compared with lean individuals and the levels correlated positively to each other. In addition, PBMC expression of OPN was high in obese individuals which also correlated with IL-18 expression by same cell population. It is previously known that OPN is highly upregulated in adipose tissue from obese humans and mice, and is functionally involved in the pathogenesis of obesity-induced adipose tissue inflammation and associated insulin resistance in mice. Several studies in mice models supported the role of OPN as a potential factor involved in obesity-induced complications [19,35]. Circulating levels of IL-18 are elevated in obesity and correlate with body mass index, adiposity and insulin resistance [34]. Not surprisingly, IL-18 concentration is high in adipose tissue. In the present study, the data show that the expression of both OPN and IL-18 was simultaneously increased in the adipose tissues from overweight/obese individuals. These findings support a model in which adipose tissue OPN is progressively increased with the increase of IL-18 levels. Interestingly, as opposed to lean individuals, OPN expression in obese individuals was found to be elevated in the circulation as well as adipose tissue.

We argue that IL-18 levels are elevated during obesity-induced inflammation, a condition which favors upregulation of the OPN...
in circulation and adipose tissue. This prompted us to investigate whether OPN was expressed in response to IL-18 activation of PBMCs. In this regard, we show for the first time that OPN expression was induced in PBMCs treated with rhIL-18. Similarly, a murine model study demonstrated parallel increases in IL-18, OPN expression and interstitial fibrosis in primary cardiac fibroblast cultures [36]. IL-18 activates the transcriptional factors AP-1 and NF-κB in T lymphocytes that show upregulated transcription of the OPN gene [37,38]. We also observed that the ex vivo production of OPN by cultured PBMCs was higher in obese than lean individuals. This may be due, in part, to the fact that T cells and monocytes/macrophages in obese individuals, unlike their lean counterparts, are in a state of chronic activation which, further leading to enhanced production of OPN by these immune regulatory cells. Increased circulatory levels of OPN will further exacerbate immune cell activation. Apart from Th1-cell activation, OPN can also activate macrophage adhesion, migration, and cytokine release [15,39]. Our present findings, therefore, support the increased ex vivo production of OPN during the process of obesity induced inflammation.

Chronic systemic inflammation is considered to play an important role in the development of diabetes and it may represent a unifying link between metabolic syndrome, type 2 diabetes, and cardiovascular disease. To explain a link between inflammation and insulin resistance, it was proposed that OPN might cause accumulation of the macrophages in adipose tissue and lead to an increased macrophage-related inflammatory activity [19,40,41]. Consistent with the previous cross-sectional studies [26,42,43], our data also show that the circulating IL-18 and OPN levels increased progressively with the escalating BMI values. After stepwise multiple linear regression analysis both OPN and IL-18 were found to be independently associated with BMI (P<0.05) which indicated that obesity contributed to the upregulation of OPN and IL-18 levels in plasma and in PBMCs. This independent association of OPN and IL-18 with obesity may aggravate inflammation status in obese individuals and affect insulin resistance as well. Although a significant correlation of OPN and IL-18 with FBG, multiple regression analysis detected only significant independent association of IL-18 with FBG, indicating that the relationship of IL-18 with FBG is dependent on obesity. Since obesity has independent association with both OPN and IL-18, OPN and IL-18 showed a positive correlation with the fasting blood glucose which may be taken as a reasonable surrogate measure of the insulin resistance. Previously it has been shown in different studies that high expression of OPN and IL-18 correlated with obesity-induced inflammation and insulin resistance [32,33,44,45]. In this particular scenario, the relation-

| Inflammatory Mediator | Metabolic Parameters | Plasma Pearson r | P | PBMCs Pearson r | P |
|-----------------------|---------------------|----------------|---|----------------|---|
| OPN                  | BMI                 | 0.4995         | 0.0002*** | 0.5171         | <0.0001*** |
|                      | Fasting Blood Glucose (mmol/l) | 0.3267 | 0.0206* | 0.2644 | 0.0412* |
|                      | HDL cholesterol (mmole/l) | 0.1220 | 0.3986 | −0.2084 | 0.1070 |
|                      | LDL cholesterol (mmol/l) | −0.08 | 0.5653 | −0.0048 | 0.9705 |
|                      | Triglycerides (mmol/l) | 0.14 | 0.2989 | 0.4614 | 0.002** |
|                      | Cholesterol (mmol/l) | −0.1214 | 0.4012 | 0.2480 | 0.0539 |
|                      | HbA1C | 0.2550 | 0.0770 | 0.4041 | 0.0014** |
| IL-18                | BMI                 | 0.3443 | 0.0166* | 0.4308 | 0.0003*** |
|                      | Fasting Blood Glucose (mmol/l) | 0.406 | 0.0042** | 0.2596 | 0.0452*
|                      | HDL cholesterol (mmole/l) | 0.211 | 0.148 | −0.2988 | 0.019* |
|                      | LDL cholesterol (mmol/l) | −0.2518 | 0.0877 | −0.0106 | 0.9357 |
|                      | Triglycerides (mmol/l) | 0.2431 | 0.095 | 0.2472 | 0.0569 |
|                      | Cholesterol (mmol/l) | −0.066 | 0.654 | 0.0187 | 0.8861 |
|                      | HbA1C | 0.300 | 0.0405* | 0.2677 | 0.0426* |

doi:10.1371/journal.pone.0063944.t002

| Inflammatory mediators | Metabolic Parameters | Plasma | PBMCs |
|-----------------------|---------------------|--------|-------|
|                      | BMI                 | β      | P value | β | P value |
| OPN                  | BMI                 | 0.516  | <0.001 | 0.400 | 0.001 |
|                      | Triglycerides       | −      | −      | 0.341 | 0.003 |
| IL-18                | BMI                 | 0.283  | 0.034  | 0.376 | 0.003 |
|                      | Fasting Glucose     | 0.388  | 0.004  | −    | −     |

doi:10.1371/journal.pone.0063944.t003
ship between OPN and IL-18 could be very crucial in development of insulin resistance in obese individuals. In summary, we show for the first time that plasma, PBMCs and adipose tissue OPN and IL-18 levels are simultaneously increased and correlate with each other in overweight/obese individuals which may trigger the development of insulin resistance. This study also provides the direct evidence that IL-18 regulates OPN and correlate with each other in overweight/obese individuals and obese individuals with a combined OPN/IL-18 elevation may be at a greater risk for developing insulin resistance as compared with non-obese population.

References

1. Greenberg AS, Ohin MS (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83: 4615–4658.
2. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. The Journal of Clinical Investigation 116: 1793–1801.
3. Lyon C, Law RE, Hsueh WA (2005) Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144: 2195–2200.
4. Hotamisligil GS, Spiegelman BM (1995) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87–91.
5. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196–4200.
6. Blackburn P, Despres JP, Lamarche B, Tremblay A, Bergeron J, et al. (2003) Postprandial variations of plasma inflammatory markers in abdominally obese men. Obesity (Silver Spring) 11(4): 1747–1754.
7. Eder K, Raffy N, Falus A, Fulop AK (2009) The major inflammatory mediator IL-6 is over-expressed in subcutaneous adipose tissue from morbidly obese patients. Endocrinology 150: 727–736.
8. Gustafson B (2010) Adipose Tissue, Inflammation and Atherosclerosis. J Atheroscler Thromb 17: 332–41.
9. Weinberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796–1808.
10. Curat CA, Miravalle A, Sengenes C, Dihl M, Tonus C, et al. (2004) From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53: 1293–1292.
11. Patarca R, Freeman GJ, Singh RP, Wei FY, Durfee T, et al. (1989) Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of novel T cell-dependent responses associated with genetic resistance to bacterial infection. J Exp Med 170: 145–161.
12. Kawamura K, Iyogna K, Ichiiyama H, Nagano J, Suga M, et al. (2005) Differmuration, maturation, and survival of dendritic cells by osteopontin regulation. Clin Diagn Lab Immunol 12: 296–312.
13. Sodek J, Raszka A, Calandra M, Zohar R (2006) Osteopontin and mucosal protection. J Dent Res 85: 404–415.
14. Bellahcene A, Castronovo V, Ogureeka KL, Fisher LW, Fedarko NS (2000) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 5: 212–226.
15. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M (1998) Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 152: 553–558.
16. Nystrom T, Duner P, Huigjard-Holsson A (2007) A constitutive endothogenous osteopontin production is important for macrophage function and differentiation. Exp Cell Res 313: 1149–1168.
17. Murry CE, Giachelli CM, Schwartz SM, Vracker RE (1994) Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 145: 1450–1462.
18. Schack L, Stupolinio R, Christensen B, Kofod-Olsen E, Skov Sorensen UB, et al. (2009) Osteopontin enhances phagocytosis through a novel osteopontin receptor, the alphaXbeta2 integrin. J Immunol 182: 6943–6950.
19. Nomiyama T, Perez-Tileve D, Ogasawa D, Gizard F, Zhao Y, et al. (2007) Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 117: 2677–2688.
20. Tatsuzaki D, Dionysiou CA (2006) IL-18 in autoimmunity: review. Eur Cytokine Netw 17: 224–232.
21. Esposito K, Portillo A, Ciorto M, Di Palo G, Grella E, et al. (2002) Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 87: 3864–3869.
22. Zhao W, Wang L, Zhang M, Wang P, Zhang L, et al. (2011) NF-kappaB and AP-1-mediated DNA looping regulates osteopontin transcription in endotoxin-stimulated murine macrophages. J Immunol 186: 3173–3179.
23. Greene CM, Meachery G, Taggart CC, Rooney CP, Coakley R, et al. (2000) Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol 165: 4718–4724.
24. Mihali D, Dwarkanath RS, Reddy MA, Lamings L, Tedorev L, et al. (2005) Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 96: 1064–1071.
25. Reddy VS, Prabhu SD, Murrishi S, Valenje AJ, Venkatatesan B, et al. (2010) Interleukin-18 induces EMPRRIN expression in primary cardiomycocytes via JNK/SAP1 signaling and MMP9 in part through EMPRRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol 299: H2124–1254.
26. Greene-Ambrogi J, Catalan V, Ramirez B, Rodriguez A, Colina I, et al. (2007) Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 92: 3719–3727.
27. Zeyda M, Gollinger K, Toledte J, Kiefer FW, Keck M, et al. (2011) Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology 152: 2219–2227.
28. Leick L, Lindegaard T, Stensvold D, Plomgaard P, Salm P, et al. (2007) Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effect of obesity and exercise. Obesity (Silver Spring) 15: 356–363.
29. Osborn O, Gram H, Zorilla EP, Conti B, Barttii T (2008) Insights into the roles of the inflammatory mediators IL-1, IL-18 and PG2E2 in obesity and insulin resistance. Swiss Med Wkly 138: 653–673.
30. Ahmad A, Ahmed R, Toma E, Morisset R, Menozzo J (2000) Impaired induction of IL-15 in response to herpes simplex virus type 1 infection in peripheral blood mononuclear cells of HIV-infected patients. AIDS 14: 744–746.
31. Leck KJ, Schmitz TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC(T) Method. Methods 23: 402–408.
32. Bertola A, Deveaux V, Bouffouis S, Rousseau D, Anty R, et al. (2009) Elevated expression of osteopontin may be related to adipose tissue macrophage infiltration and liver steatosis in morbid obesity. Diabetes 58: 125–133.
33. Kiefer FW, Zeyda M, Gollinger K, Piau B, Neuhofer A, et al. (2010) Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 59: 935–946.
34. Bruun JM, Skalnakeht B, Hege JW, Riechenb (2007) Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol 157: 463–471.
35. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whiting PS (2004) Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 287: G264–G273.
36. Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, et al. (2009) IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol 297: H476–85.
37. Ogawa D, Stone JF, Takata Y, Blachke F, Chu VH, et al. (2005) Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ Res 96: e39–67.
38. Shinohara ML, Janssen M, Haw W, Newmark BH, Gilbcher JPLH, et al. (2005) T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci U S A 102: 17101–17106.
39. Ashkar S, Weber GF, Panoustakopoulos V, Sanchirico ME, Jansson M, et al. (2005) Interleukin-18 induces EMPRRIN expression in primary cardiomycocytes via JNK/SAP1 signaling and MMP9 in part through EMPRRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol 299: H2124–1254.
41. Kamei N, Tobe K, Suzuki R, Obusui M, Watanabe T, et al. (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602–26614.
42. Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan AJ, et al. (2001) Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 86: 4398–4405.
43. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP (2005) Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 25: 1268–1273.
44. Zhang YF, Yang YS, Hong J, Gu WQ, Shen CF, et al. (2006) Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 29: 419–423.
45. Sun L, Hu FB, Yu Z, Li H, Liu H, et al. (2011) Lean body mass, interleukin 18, and metabolic syndrome in apparently healthy Chinese. PLoS One 6: e18104.